blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2960652

EP2960652 - COMPOSITIONS AND METHODS FOR CHARACTERIZING A MYOPATHY [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  10.07.2020
Database last updated on 08.06.2024
FormerThe patent has been granted
Status updated on  02.08.2019
FormerGrant of patent is intended
Status updated on  02.12.2018
FormerExamination is in progress
Status updated on  04.11.2016
Most recent event   Tooltip08.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 10.08.2022  [2022/32]
Applicant(s)For all designated states
The Johns Hopkins University
3400 North Charles Street
Baltimore, MD 21218 / US
[2016/01]
Inventor(s)01 / CASCIOLA-ROSEN, Livia Angela
3 Stone Hollow Ct.
Pikesville, MD 21208 / US
02 / CHRISTOPHER-STINE, Lisa
c/o Johns Hopkins Myositis Center
5200 Eastern Avenue
Mason F. Lord Building
Center Tower, Suite 4500
Baltimore, MD 21224 / US
03 / MAMMEN, Andrew
c/o Johns Hopkins Myositis Center
5200 Eastern Avenue
Mason F. Lord Building
Center Tower, Suite 4500
Baltimore, MD 21224 / US
04 / ROSEN, Antony
3 Stone Hollow Ct.
Pikesville, MD 21208 / US
 [2016/01]
Representative(s)Hiebl, Inge Elisabeth
Kraus & Weisert
Patentanwälte PartGmbB
Thomas-Wimmer-Ring 15
80539 München / DE
[2016/01]
Application number, filing date15164007.515.04.2011
[2016/01]
Priority number, dateUS20100324857P16.04.2010         Original published format: US 324857 P
US20100371798P09.08.2010         Original published format: US 371798 P
[2016/01]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP2960652
Date:30.12.2015
Language:EN
[2015/53]
Type: B1 Patent specification 
No.:EP2960652
Date:04.09.2019
Language:EN
[2019/36]
Search report(s)(Supplementary) European search report - dispatched on:EP03.11.2015
ClassificationIPC:G01N33/564, G01N33/573
[2018/50]
CPC:
G01N33/573 (EP,US); G01N33/564 (EP,US); G01N2333/902 (EP,US);
G01N2333/904 (US); G01N2800/10 (EP,US)
Former IPC [2016/01]G01N33/564, G01N33/573, G01N33/532, G01N33/534, G01N33/15
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2016/32]
Former [2016/01]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  RS,  SE,  SI,  SK,  SM,  TR 
TitleGerman:ZUSAMMENSETZUNGEN UND VERFAHREN ZUR CHARAKTERISIERUNG EINER MYOPATHIE[2016/01]
English:COMPOSITIONS AND METHODS FOR CHARACTERIZING A MYOPATHY[2016/01]
French:COMPOSITIONS ET MÉTHODES POUR LA CARACTÉRISATION D'UNE MYOPATHIE[2016/01]
Examination procedure30.06.2016Amendment by applicant (claims and/or description)
30.06.2016Examination requested  [2016/32]
08.11.2016Despatch of a communication from the examining division (Time limit: M04)
02.03.2017Reply to a communication from the examining division
08.05.2017Despatch of a communication from the examining division (Time limit: M06)
22.01.2018Reply to a communication from the examining division
30.10.2018Observations by third parties
19.11.2018Cancellation of oral proceeding that was planned for 30.11.2018
30.11.2018Date of oral proceedings (cancelled)
03.12.2018Communication of intention to grant the patent
21.05.2019Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time
26.07.2019Fee for grant paid
26.07.2019Fee for publishing/printing paid
26.07.2019Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP11769677.3  / EP2558863
Opposition(s)05.06.2020No opposition filed within time limit [2020/33]
Request for further processing for:The application is deemed to be withdrawn due to failure to fulfill actions required for granting the patent
26.07.2019Request for further processing filed
26.07.2019Full payment received (date of receipt of payment)
Request granted
05.08.2019Decision despatched
The application is deemed to be withdrawn due to failure to reply to the examination report
22.01.2018Request for further processing filed
22.01.2018Full payment received (date of receipt of payment)
Request granted
08.02.2018Decision despatched
Fees paidRenewal fee
12.05.2015Renewal fee patent year 03
12.05.2015Renewal fee patent year 04
12.05.2015Renewal fee patent year 05
27.04.2016Renewal fee patent year 06
27.04.2017Renewal fee patent year 07
27.04.2018Renewal fee patent year 08
29.04.2019Renewal fee patent year 09
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU15.04.2011
AL04.09.2019
AT04.09.2019
CY04.09.2019
CZ04.09.2019
DK04.09.2019
EE04.09.2019
ES04.09.2019
FI04.09.2019
HR04.09.2019
IT04.09.2019
LT04.09.2019
LV04.09.2019
MC04.09.2019
MK04.09.2019
MT04.09.2019
NL04.09.2019
PL04.09.2019
RO04.09.2019
RS04.09.2019
SE04.09.2019
SI04.09.2019
SK04.09.2019
SM04.09.2019
TR04.09.2019
BG04.12.2019
NO04.12.2019
GR05.12.2019
IS05.01.2020
PT06.01.2020
IE15.04.2020
LU15.04.2020
BE30.04.2020
[2022/32]
Former [2022/27]HU15.04.2011
AL04.09.2019
AT04.09.2019
CY04.09.2019
CZ04.09.2019
DK04.09.2019
EE04.09.2019
ES04.09.2019
FI04.09.2019
HR04.09.2019
IT04.09.2019
LT04.09.2019
LV04.09.2019
MC04.09.2019
MT04.09.2019
NL04.09.2019
PL04.09.2019
RO04.09.2019
RS04.09.2019
SE04.09.2019
SI04.09.2019
SK04.09.2019
SM04.09.2019
TR04.09.2019
BG04.12.2019
NO04.12.2019
GR05.12.2019
IS05.01.2020
PT06.01.2020
IE15.04.2020
LU15.04.2020
BE30.04.2020
Former [2021/20]AL04.09.2019
AT04.09.2019
CZ04.09.2019
DK04.09.2019
EE04.09.2019
ES04.09.2019
FI04.09.2019
HR04.09.2019
IT04.09.2019
LT04.09.2019
LV04.09.2019
MC04.09.2019
NL04.09.2019
PL04.09.2019
RO04.09.2019
RS04.09.2019
SE04.09.2019
SI04.09.2019
SK04.09.2019
SM04.09.2019
BG04.12.2019
NO04.12.2019
GR05.12.2019
IS05.01.2020
PT06.01.2020
IE15.04.2020
LU15.04.2020
BE30.04.2020
Former [2021/12]AL04.09.2019
AT04.09.2019
CZ04.09.2019
DK04.09.2019
EE04.09.2019
ES04.09.2019
FI04.09.2019
HR04.09.2019
IT04.09.2019
LT04.09.2019
LV04.09.2019
MC04.09.2019
NL04.09.2019
PL04.09.2019
RO04.09.2019
RS04.09.2019
SE04.09.2019
SI04.09.2019
SK04.09.2019
SM04.09.2019
BG04.12.2019
NO04.12.2019
GR05.12.2019
IS05.01.2020
PT06.01.2020
LU15.04.2020
BE30.04.2020
Former [2021/08]AL04.09.2019
AT04.09.2019
CZ04.09.2019
DK04.09.2019
EE04.09.2019
ES04.09.2019
FI04.09.2019
HR04.09.2019
IT04.09.2019
LT04.09.2019
LV04.09.2019
MC04.09.2019
NL04.09.2019
PL04.09.2019
RO04.09.2019
RS04.09.2019
SE04.09.2019
SI04.09.2019
SK04.09.2019
SM04.09.2019
BG04.12.2019
NO04.12.2019
GR05.12.2019
IS05.01.2020
PT06.01.2020
LU15.04.2020
Former [2020/52]AL04.09.2019
AT04.09.2019
CZ04.09.2019
DK04.09.2019
EE04.09.2019
ES04.09.2019
FI04.09.2019
HR04.09.2019
IT04.09.2019
LT04.09.2019
LV04.09.2019
MC04.09.2019
NL04.09.2019
PL04.09.2019
RO04.09.2019
RS04.09.2019
SE04.09.2019
SI04.09.2019
SK04.09.2019
SM04.09.2019
BG04.12.2019
NO04.12.2019
GR05.12.2019
IS05.01.2020
PT06.01.2020
Former [2020/37]AL04.09.2019
AT04.09.2019
CZ04.09.2019
DK04.09.2019
EE04.09.2019
ES04.09.2019
FI04.09.2019
HR04.09.2019
IT04.09.2019
LT04.09.2019
LV04.09.2019
NL04.09.2019
PL04.09.2019
RO04.09.2019
RS04.09.2019
SE04.09.2019
SI04.09.2019
SK04.09.2019
SM04.09.2019
BG04.12.2019
NO04.12.2019
GR05.12.2019
IS05.01.2020
PT06.01.2020
Former [2020/36]AL04.09.2019
AT04.09.2019
CZ04.09.2019
DK04.09.2019
EE04.09.2019
ES04.09.2019
FI04.09.2019
HR04.09.2019
IT04.09.2019
LT04.09.2019
LV04.09.2019
NL04.09.2019
PL04.09.2019
RO04.09.2019
RS04.09.2019
SE04.09.2019
SK04.09.2019
SM04.09.2019
BG04.12.2019
NO04.12.2019
GR05.12.2019
IS05.01.2020
PT06.01.2020
Former [2020/27]AL04.09.2019
AT04.09.2019
CZ04.09.2019
EE04.09.2019
ES04.09.2019
FI04.09.2019
HR04.09.2019
IT04.09.2019
LT04.09.2019
LV04.09.2019
NL04.09.2019
PL04.09.2019
RO04.09.2019
RS04.09.2019
SE04.09.2019
SK04.09.2019
SM04.09.2019
BG04.12.2019
NO04.12.2019
GR05.12.2019
PT06.01.2020
IS24.02.2020
Former [2020/25]AL04.09.2019
AT04.09.2019
CZ04.09.2019
EE04.09.2019
ES04.09.2019
FI04.09.2019
HR04.09.2019
IT04.09.2019
LT04.09.2019
LV04.09.2019
NL04.09.2019
PL04.09.2019
RO04.09.2019
RS04.09.2019
SE04.09.2019
SK04.09.2019
BG04.12.2019
NO04.12.2019
GR05.12.2019
PT06.01.2020
IS24.02.2020
Former [2020/24]AL04.09.2019
AT04.09.2019
EE04.09.2019
ES04.09.2019
FI04.09.2019
HR04.09.2019
IT04.09.2019
LT04.09.2019
LV04.09.2019
NL04.09.2019
PL04.09.2019
RO04.09.2019
RS04.09.2019
SE04.09.2019
BG04.12.2019
NO04.12.2019
GR05.12.2019
PT06.01.2020
IS24.02.2020
Former [2020/23]AL04.09.2019
AT04.09.2019
EE04.09.2019
ES04.09.2019
FI04.09.2019
HR04.09.2019
IT04.09.2019
LT04.09.2019
LV04.09.2019
NL04.09.2019
PL04.09.2019
RO04.09.2019
RS04.09.2019
SE04.09.2019
BG04.12.2019
NO04.12.2019
GR05.12.2019
PT06.01.2020
Former [2020/22]AL04.09.2019
EE04.09.2019
ES04.09.2019
FI04.09.2019
HR04.09.2019
LT04.09.2019
LV04.09.2019
NL04.09.2019
RS04.09.2019
SE04.09.2019
BG04.12.2019
NO04.12.2019
GR05.12.2019
PT06.01.2020
Former [2020/20]AL04.09.2019
ES04.09.2019
FI04.09.2019
HR04.09.2019
LT04.09.2019
LV04.09.2019
NL04.09.2019
RS04.09.2019
SE04.09.2019
BG04.12.2019
NO04.12.2019
GR05.12.2019
Former [2020/15]AL04.09.2019
ES04.09.2019
FI04.09.2019
HR04.09.2019
LT04.09.2019
LV04.09.2019
RS04.09.2019
SE04.09.2019
BG04.12.2019
NO04.12.2019
GR05.12.2019
Former [2020/11]ES04.09.2019
FI04.09.2019
HR04.09.2019
LT04.09.2019
LV04.09.2019
RS04.09.2019
SE04.09.2019
BG04.12.2019
NO04.12.2019
GR05.12.2019
Former [2020/10]FI04.09.2019
LT04.09.2019
SE04.09.2019
BG04.12.2019
NO04.12.2019
Former [2020/09]FI04.09.2019
LT04.09.2019
NO04.12.2019
Former [2020/08]LT04.09.2019
NO04.12.2019
Documents cited:Search[A]WO2007061995  (NOVARTIS AG [CH], et al) [A] 1-15* the whole document *;
 [X]  - FUHRMAN ET AL, "Urokinase plasminogen activator (uPA) stimulates cholesterol biosynthesis in macrophages through activation of SREBP-1 in a PI3-kinase and MEK-dependent manner", ATHEROSCLEROSIS, ELSEVIER IRELAND LTD, IE, (20071114), vol. 195, no. 2, doi:10.1016/J.ATHEROSCLEROSIS.2007.06.025, ISSN 0021-9150, pages e108 - e116, XP022344956 [X] 15 * paragraph [02.8] *

DOI:   http://dx.doi.org/10.1016/j.atherosclerosis.2007.06.025
 [L]  - "HMGCR (C-18): sc-27578 - Antibody datasheet", ISBN 978-0-12-198390-1, (20150101), page 1, URL: http://datasheets.scbt.com/sc-27578.pdf, (20151019), XP055222045 [L] * This document completes the disclosure of Fuhrman et al. regarding the anti-HMGCR antibody * * Paragraph "Source" *
 [X]  - CLARK ET AL, "Production and characterization of monoclonal antibodies to rat liver microsomal 3-hydroxy-3-methylglutaryl-coenzyme A reductase.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, (19820601), vol. 79, no. 12, ISSN 0027-8424, pages 3734 - 3738, XP055075565 [X] 15 * abstract *

DOI:   http://dx.doi.org/10.1073/pnas.79.12.3734
 [XP]  - ANDREW L. MAMMEN ET AL, "Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy", ARTHRITIS & RHEUMATISM, (20110301), vol. 63, no. 3, doi:10.1002/art.30156, ISSN 0004-3591, pages 713 - 721, XP055075417 [XP] 1-15 * abstract * * page 714, column left * * paragraph "Anti-HMGCR ELISA" * * page 719, column right *

DOI:   http://dx.doi.org/10.1002/art.30156
 [XP]  - LISA CHRISTOPHER-STINE ET AL, "A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy", ARTHRITIS & RHEUMATISM, (20100523), vol. 62, no. 9, doi:10.1002/art.27572, ISSN 0004-3591, pages 2757 - 2766, XP055075421 [XP] 1-15 * abstract * * page 2758, column left, paragraph 2 - paragraph 3 * * page 2761 - page 2762, bridging paragraph * * page 2764, column left * * page 2765, column right *

DOI:   http://dx.doi.org/10.1002/art.27572
 [L]  - Christopher-Stine, "A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy", (20100523), URL: http://onlinelibrary.wiley.com/doi/10.1002/art.27572/full, (20130815), XP055075425 [L] * Document indicating the online publication date of the article of Lisa Christopher-Stine et al. * * the whole document *

DOI:   http://dx.doi.org/10.1002/art.27572
 [AD]  - G J D HENGSTMAN ET AL, "Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy", ANNALS OF THE RHEUMATIC DISEASES, (20060525), vol. 65, no. 12, doi:10.1136/ard.2006.052191, ISSN 0003-4967, pages 1635 - 1638, XP055075612 [AD] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.1136/ard.2006.052191
 [A]  - IRA N. TARGOFF, "Autoantibodies and their significance in myositis", CURRENT RHEUMATOLOGY REPORTS, (20080801), vol. 10, no. 4, doi:10.1007/s11926-008-0053-2, ISSN 1523-3774, pages 333 - 340, XP055075592 [A] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.1007/s11926-008-0053-2
by applicant   - DE SAUVAGE NOLTING ET AL., AM J CARDIOL, (2002), vol. 90, pages 181 - 4
    - BRUCKERT ET AL., CARDIOVASC DRUGS THER, (2005), vol. 19, pages 403 - 14
    - FRANC ET AL., CARDIOVASC DRUGS THER, (2003), vol. 17, pages 459 - 65
    - GRAHAM ET AL., JAMA, (2004), vol. 292, pages 2585 - 90
    - SOININEN ET AL., BASIC CLIN PHARMACOL TOXICOL, (2006), vol. 98, pages 51 - 4
    - NEEDHAM ET AL., NEUROMUSCUL DISORD, (2007), vol. 17, pages 194 - 200
    - GRABLE-ESPOSITO ET AL., MUSCLE NERVE, (2010), vol. 41, pages 185 - 90
    - DALAKAS MC ET AL., LANCET, (2003), vol. 362, pages 971 - 82
    - MAMMEN AL, ANN N YACAD SCI, (2010), vol. 1184, pages 134 - 53
    - TARGOFF IN ET AL., RHEUM DIS CLIN NORTH AM, (2002), vol. 28, pages 859 - 90
    - YOSHIDA S ET AL., ARTHRITIS RHEUM, (1983), vol. 26, pages 604 - 11
    - MARGUERIE C ET AL., QJMED, (1990), vol. 77, pages 1019 - 38
    - MILLER T ET AL., JNEUROL NEUROSURG PSYCHIATRY, (2002), vol. 73, pages 420 - 8
    - KAO AH ET AL., ARTHRITIS RHEUM, (2004), vol. 50, pages 209 - 15
    - HENGSTMAN GJ ET AL., ANN RHEUM DIS, (2006), vol. 65, pages 1635 - 8
    - DIMITRI D ET AL., MUSCLE NERVE, (2007), vol. 35, pages 389 - 95
    - KISSEL JT ET AL., N ENGL J MED, (1986), vol. 314, pages 329 - 34
    - EMSLIE-SMITH AM ET AL., ANN NEUROL, (1990), vol. 27, pages 343 - 56
    - SPULER S ET AL., NEUROLOGY, (1998), vol. 50, pages 41 - 6
    - EMSLIE-SMITH AM; ENGEL AG, NEUROLOGY, (1991), vol. 41, pages 936 - 9
    - OXENHANDLER R ET AL., HUM PATHOL, (1982), vol. 13, pages 745 - 57
    - MILLER T ET AL., J NEUROL NEUROSURG PSYCHIATRY, (2002), vol. 73, pages 420 - 8
    - VAN DER PAS J ET AL., JNEUROL NEUROSURG PSYCHIATRY, (2004), vol. 75, pages 136 - 9
    - SUNDARAM C ET AL., NEUROL INDIA, (2008), vol. 56, pages 363 - 7
    - GOLDSTEIN JL; BROWN MS, NATURE, (1990), vol. 343, pages 425 - 30
    - MORIKAWA S ET AL., JATHEROSCLER THROMB, (2005), vol. 12, pages 121 - 31
    - N ENGL JMED, (2008), vol. 359, pages 789 - 99
    - CASCIOLA-ROSEN ET AL., JEXP MED, (2005), vol. 201, pages 591 - 601
    - MAMMEN, ARTHRITIS RHEUM, (2009), vol. 60, pages 3784 - 93
    - PARKER ET AL., J BIOL CHEM, (1989), vol. 264, pages 4877 - 87
    - BOHAN; PETER, N ENGL J MED, (1975), vol. 292, pages 344 - 7
    - N ENGL J MED, vol. 292, pages 403 - 7
    - GRIGGS RC ET AL., ANN NEUROL, (1995), vol. 38, pages 705 - 13
    - BOHAN; PETER, N ENGL J MED, (1975), vol. 292, pages 344 - 7,403-7
    - GRIGGS ET AL., ANN NEUROL, (1995), vol. 38, pages 705 - 13
otherWO2011130647
 EP2558863
 EP2558863
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.